


Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)	<b>ATTY. DOCKET NO.</b> 0253.410US/16384US04	<b>SERIAL NO.</b> 10/521,008
	<b>APPLICANT(s):</b> Van Den Hazel, et al.	
	<b>FILING DATE</b> 01/03/2005	<b>GROUP ART UNIT:</b> Not yet assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,457,867	07/03/84	Ishida, T.			
	A2	4,588,585	05/13/86	Mark, <i>et al.</i>			
	A3	4,604,284	08/05/86	Kung, <i>et al.</i>			
	A4	4,695,623	09/22/87	Stabinsky, Y.			
	A5	4,727,138	02/23/88	Goeddel, <i>et al.</i>			
	A6	4,758,656	07/19/88	Itoh, <i>et al.</i>			
	A7	4,762,791	08/09/88	Goeddel, <i>et al.</i>			
	A8	4,832,959	05/23/89	Engels, <i>et al.</i>			
	A9	4,835,256	05/30/89	Taniguchi, <i>et al.</i>			
	A10	4,845,196	07/04/89	Cowling, G.J.			
	A11	4,855,238	08/08/89	Gray, <i>et al.</i>			
	A12	4,897,471	01/30/90	Stabinsky, Y.			
	A13	4,898,931	02/06/90	Itoh, <i>et al.</i>			
	A14	4,904,584	02/27/90	Shaw, G.			
	A15	4,921,698	05/01/90	Shirai, <i>et al.</i>			
	A16	4,925,793	05/15/90	Goeddel, <i>et al.</i>			
	A17	4,929,554	05/29/90	Goeddel, <i>et al.</i>			
	A18	4,944,941	07/31/90	Ammann, A.J.			
	A19	4,966,843	10/30/90	McCormick, <i>et al.</i>			
	A20	4,980,455	12/25/90	Sakaguchi, <i>et al.</i>			
	A21	5,004,689	04/02/91	Fiers, <i>et al.</i>			
	A22	5,041,376	08/20/91	Gething, <i>et al.</i>			
	A23	5,096,705	03/17/92	Goeddel, <i>et al.</i>			
	A24	5,109,120	04/28/92	Ueno, <i>et al.</i>			
	A25	5,157,004	11/20/92	Sakaguchi, <i>et al.</i>			
	A26	5,362,490	11/08/94	Kurimoto, <i>et al.</i>			
	A27	5,376,567	12/27/94	McCormick, <i>et al.</i>			
	A28	5,382,657	01/17/95	Karasiewicz, <i>et al.</i>			
	A29	5,518,899	05/21/96	Kurimoto, <i>et al.</i>			
	A30	5,541,293	07/30/96	Stabinsky, Y.			
	A31	5,554,515	09/10/96	Kurimoto, <i>et al.</i>			
	A32	5,574,137	11/12/96	Gray, <i>et al.</i>			
	A33	5,582,824	12/10/96	Goeddel, <i>et al.</i>			
	A34	5,595,888	01/21/97	Gray <i>et al.</i>			

EXAMINER

DATE CONSIDERED:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1800-786-9199) and select option 2.

Rev. Sept. 03

J:\Open\Jdp\MaXygen ApS\USPTO\16384US04\16384US04 - PTO Form SB08A.doc

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>ATTY. DOCKET NO.</b> 0253.410US/16384US04	<b>SERIAL NO.</b> 10/521,008
	<b>APPLICANT(s):</b> Van Den Hazel, et al.	
	<b>FILING DATE</b> 01/03/2005	<b>GROUP ART UNIT:</b> Not yet assigned

**U.S. PATENT DOCUMENTS**

A35	5,661,009	08/26/97	Stabinsky, Y.			
A36	5,672,692	09/30/97	Kurimoto, et al.			
A37	5,690,925	11/25/97	Gray, et al.			
A38	5,711,944	01/27/98	Gilbert, et al.			
A39	5,723,121	03/03/98	Takenaga, et al.			
A40	5,738,846	04/14/98	Greenwald, et al.			
A41	5,747,646	05/05/98	Hakimi, et al.			
A42	5,792,834	08/11/98	Hakimi, et al.			
A43	6,042,822	03/28/00	Gilbert, et al.			
A44	6,046,034	04/04/00	Waschutza, et al.			
A45	6,120,762	09/19/00	Johnson, et al.			
A46	6,770,191	06/23/98	Johnson, et al.			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NO.	PUBLICATI ON DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B1	077 670 B1	04/27/83	EP				
	B2	088 540 A2	09/14/83	EP				
	B3	089 676 A2	09/28/83	EP				
	B4	098 110 A2	01/11/84	EP				
	B5	110 044 A1	06/13/84	EP				
	B6	121 157 B1	06/14/89	EP				
	B7	145 174 B1	09/13/89	EP				
	B8	146 354 A2	06/26/85	EP				
	B9	158 198 A1	10/16/85	EP				
	B10	170 917 B1	02/12/86	EP				
	B11	219 781 A2	04/29/87	EP				
	B12	229 108 B1	07/22/87	EP				
	B13	236 987 B1	09/16/87	EP				
	B14	237 019 A2	09/16/87	EP				
	B15	256 424 B1	08/04/87	EP				
	B16	306 870 A2	03/15/89	EP				
	B17	370 205 A2	05/30/90	EP				

EXAMINER

DATE CONSIDERED:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1800-786-9199) and select option 2.

Rev. Sept. 03

J:\Open\Djp\MaXygen ApS\USPTO\16384US04\16384US04 - PTO Form SB08A.doc

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>ATTY. DOCKET NO.</b> 0253.410US/16384US04	<b>SERIAL NO.</b> 10/521,008
	<b>APPLICANT(s):</b> Van Den Hazel, et al.	
	<b>FILING DATE</b> 01/03/2005	<b>GROUP ART UNIT:</b> Not yet assigned

**FOREIGN PATENT DOCUMENTS**

B18	446 582 B1	09/18/91	EP				
B19	546 099 B1	10/12/94	EP				
B20	593 868 B1	04/15/98	EP				
B21	795 332 A2	09/17/97	EP				
B22	860 442 A1	08/26/98	EP				
B23	92/08737 A1	11/14/91	WO				
B24	92/22310 A1	06/19/92	WO				
B25	99/03887 A1	07/13/98	WO				
B26	99/67291 A2	06/18/99	WO				
B27	01/23006 A1	09/28/00	WO				
B28	01/36001 A2	11/13/00	WO				
B29	2 096 532	05/29/92	CA				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

C1	Arakawa, et al., <i>Role of Polycationic c-terminal Portion in the Structure and Activity of Recombinant Human Interferon-<math>\gamma</math></i> , The Journal of Biological Chemistry, <b>261(18)</b> , June 25, pp. 8534-39 (1986).
C2	Arakawa, et al., <i>Structure and Activity of Glycosylated Human Interferon-<math>\gamma</math></i> , Journal of Interferon Research, <b>6</b> :687-695 (1986).
C3	Bulleid, et al., <i>Source of heterogeneity in secreted interferon-<math>\gamma</math></i> , Biochem. J. <b>268</b> :777-781 (1990).
C4	Cantell, et al., <i>Differential Inactivation of Interferon by a Protease from Human Granulocytes</i> , Journal of Interferon Research <b>12</b> :177-183 (1992).
C5	Castro, et al., <i>The macroheterogeneity of recombinant human interferon-<math>\gamma</math> produced by Chinese-hamster ovary cells is affected by the protein and lipid content of the culture medium</i> , Biotechnol. Appl. Biochem., <b>21</b> :87-100 (1995).
C6	Curling, et al., <i>Recombinant human interferon-<math>\gamma</math>, Differences in glycosylation and proteolytic processing lead to heterogeneity in batch culture</i> , Biochem. J., <b>272</b> :333-337 (1990).
C7	Devos, et al., <i>Molecular cloning of human immune interferon cDNA and its expression in eukaryotic cells</i> , Nucleic Acids Research, <b>10(8)</b> , 2487-2501, November 08, 1982.
C8	Ealick, et al., <i>Three-Dimensional Structure of Recombinant Human Interferon-<math>\gamma</math></i> , Science, <b>252</b> :698-702 (1991).
C9	Farrar, et al., <i>The Molecular Cell Biology of Interferon-<math>\gamma</math> and its Receptor</i> , Annu. Rev. Immunol. <b>11</b> :572-611 (1993).
C10	Gray, et al., <i>Structure of the human immune interferon gene</i> , Nature, <b>298</b> :859-863 (August 1992).

EXAMINER

DATE CONSIDERED:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1800-786-9199) and select option 2.

Rev. Sept. 03

J:\OpenDjp\MaXygen ApS\USPTO\16384US04\16384US04 - PTO Form SB08A.doc

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>ATTY. DOCKET NO.</b> 0253.410US/16384US04	<b>SERIAL NO.</b> 10/521,008
	<b>APPLICANT(s):</b> Van Den Hazel, et al.	
	<b>FILING DATE</b> 01/03/2005	<b>GROUP ART UNIT:</b> Not yet assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C11	Griggs, et al.,	<i>The N-terminus and C-Terminus of IFN-<math>\gamma</math> Are Binding Domains for Cloned Soluble IFN-<math>\gamma</math> Receptor</i> , The Journal of Immunology, 149(2) 517-520 (July 15, 1992).
C12	Gu, et al.,	<i>Improvement of Interferon-<math>\gamma</math> Sialylation in Chinese Hamster Ovary Cell culture by Feeding of N-Acetylmannosamine</i> , Biotechnology & Bioengineering, 58(6) 642-648 (1998).
C13	Haelewn, et al.,	<i>Interaction of truncated human interferon <math>\gamma</math> variants with the interferon <math>\gamma</math> receptor: crucial importance of Arg-129</i> , Biochem. J., 324, 591 – 595 (1997).
C14	Harmon, et al.,	<i>Rapid Monitoring of Site-Specific Glycosylation Microheterogeneity of Recombinant Human Interferon-<math>\gamma</math></i> , Anal. Chem., 68(9) 1465-1473 (1996).
C15	Hogrefe, et al.,	<i>Amino Terminus Is Essential to the Structural Integrity of Recombinant Human Interferon-<math>\gamma</math></i> , The Journal of Biological Chemistry, 264(21) 12179-86 (1989).
C16	Hooker, et al.,	<i>Constraints on the Transport and Glycosylation of Recombinant IFN-<math>\gamma</math> in Chinese Hamster Ovary and Insect Cells</i> , Biotechnology & Bioengineering, 63(5) 559-572 (1999).
C17	Hsu, et al.,	<i>Structure and activity of Recombinant Human Interferon-<math>\gamma</math> Analogs</i> , Journal of Interferon Research, 6:663-670 (1986).
C18	James, et al.,	<i>N-Glycosylation of Recombinant Human Interferon-<math>\gamma</math> Produced in Different Animal Expression Systems</i> , Bio/Technology, 13:592-96 (June 13, 1995).
C19	Kita, et al.,	<i>Characterization of a Polyethylene Glycol Conjugate of Recombinant Human Interferon-<math>\gamma</math></i> , Drug Design and Delivery, 6:157-167 (1990).
C20	Kontsek, et al.,	<i>Engineered Acid-Stable Human Interferon Gamma</i> , Cytokine, 12(6) 708-710 (June, 2000).
C21	Landar, et al.,	<i>Design, Characterization, and Structure of a Biologically Active Single-chain Mutant of Human IFN-<math>\gamma</math></i> , J. Mol. Biol., 299:169-179 (2000).
C22	Leinikki, et al.,	<i>Reduced Receptor Binding by a Human Interferon-<math>\gamma</math> Fragment Lacking 11 Carboxyl-Terminal Amino Acids</i> , Journal of Immunology, 139(10) 3360-3366 (1987).
C23	Littman, et al.,	<i>Binding of Unglycosylated and Glycosylated Human Recombinant Interferon-<math>\gamma</math> to Cellular Receptors</i> , Journal of Interferon Research, 5: 471-476 (1985).
C24	Lord, et al.,	<i>Functional Domains of Human Interferon Gamma Probed With Antipeptide Antibodies</i> , Molecular Immunology, 26(7) 637-640 (1989).
C25	Luk, et al.,	<i>Structure-Function Analysis of the Human Interferon <math>\gamma</math></i> , The Journal of Biological Chemistry, 265 (22) 13314-13319 (1990).
C26	Lundell, et al.,	<i>Importance of the Loop connecting A and B Helices of Human Interferon-<math>\gamma</math> in Recognition by Interferon-<math>\gamma</math> Receptor*</i> , The Journal of Biological Chemistry, 269(23) 16159-16162.
C27	Lundell, et al.,	<i>Structural Elements Required for Receptor Recognition of Human Interferon-Gamma</i> , Pharmac. Ther. 64:1-21 (1994).
C28	Lundell, et al.,	<i>The carboxyl-terminal region of human interferon <math>\gamma</math> is important for biological activity: mutagenic and NMR analysis</i> , Protein Engineering, 4(3) 335-341 (1991).

<b>EXAMINER</b>	<b>DATE CONSIDERED:</b>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="http://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p> <p>If you need assistance in completing the form, call 1-800-PTO-9199 (1800-786-9199) and select option 2.</p>	
Rev. Sept. 03 J:\Open\Jip\MaXygen Ap\SUSPTO\16384US04\16384US04 - PTO Form SB08A.doc	

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>ATTY. DOCKET NO.</b> 0253.410US/16384US04	<b>SERIAL NO.</b> 10/521,008
	<b>APPLICANT(s):</b> Van Den Hazel, et al.	
	<b>FILING DATE</b> 01/03/2005	<b>GROUP ART UNIT:</b> Not yet assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C29	Lunn, et al., <i>A point mutation of human interferon <math>\gamma</math> abolishes receptor recognition</i> , Protein Engineering, 5(3) 253-257 (1992).	
C30	Lunn, et al., <i>A point mutation that decreases the thermal stability of human interferon <math>\gamma</math></i> , Protein Engineering, 5(3) 249-252 (1992).	
C31	Mørtz, et al., <i>Mass spectrometric characterization of glycosylated interferon-<math>\gamma</math> variants separated by gel electrophoresis</i> , Electrophoresis, 17:926-931 (1996).	
C32	Nishi, et al., <i>Cloning and Expression of a Novel Variant of Human Interferon-<math>\gamma</math> cDNA</i> , J. Biochem, 97 (1) 153-159 (1985).	
C33	Nyberg, et al., <i>Metabolic Effects on Recombinant Interferon-<math>\gamma</math> Glycosylation in Continuous Culture of Chinese Hamster Ovary Cells</i> , Biotechnology & Bioengineering, 62(3) 336-347 (1999).	
C34	Oliver, et al., <i>The use of electrospray ionization MS to determine the structure of glycans in intact glycoproteins</i> , Biochem. Mass Spectro., 24:917-927 (1996).	
C35	Pan, et al., <i>Structural characterization of human interferon <math>\gamma</math></i> , FEBS 145-149 (1987).	
C36	Rinderknecht, et al., <i>Natural Human Interferon-<math>\gamma</math></i> , Journal of Biological Chemistry, 259(11) 6790-6797 (1984).	
C37	Riske, et al., <i>Characterization of Human Interferon-<math>\gamma</math> and Human Interleukin-2 from Recombinant Mammalian Cell Lines and Peripheral Blood Lymphocytes</i> , Lymphokine and Cytokine Research, 10 (3) 213-218, (1991).	
C38	Sakaguchi, et al., <i>Human interferon-<math>\gamma</math> lacking 23 COOH-terminal amino acids is biologically active</i> , FEBS Letters, 230(1,2) 201-204 (March 1988).	
C39	Sano, et al., <i>Structural Characterization of Recombinant Human Interferon-Gammas Derived from Two Different Mammalian Cells</i> , Microbiol. Immunol., 32 (5) 499-510 (1988).	
C40	Sareneva, et al., <i>Biosynthesis and N-glycosylation of human interferon-<math>\gamma</math> Asn25 and Asn97 differ markedly in how efficiently they are glycosylated and in their oligosaccharide composition</i> , Eur. J. Biochem., 242:191-200 (1996).	
C41	Sareneva, et al., <i>N-glycosylation of human interferon-<math>\gamma</math>: glycans at Asn-25 are critical for protease resistance</i> , Biochem. J. 308:9-14 (1995).	
C42	Sareneva, et al., <i>Role of N-glycosylation in the synthesis, dimerization and secretion of human interferon-<math>\gamma</math></i> , Biochem. J., 303:831-840 (1994).	
C43	Sareneva, et al., <i>Effect of Carbohydrates on the Pharmacokinetics of Human Interferon-<math>\gamma</math></i> , Journal of Interferon Research, 13:267-269 (1993).	
C44	Seelig, et al., <i>Evidence for a Polypeptide Segment at the Carboxyl Terminus of Recombinant Human <math>\gamma</math> Interferon Involved in Expression of Biological Activity</i> , Biochemistry, 27(6) 1981-1987 (1988).	
C45	Slodowski, et al., <i>Carboxy-terminal truncated rhuIFN-<math>\gamma</math> with a substitution of Gln133 o Ser132 to leucine leads to higher biological activity than in the wild type</i> , Euro. J. Biochem, 202:1133-1140 (1991).	

<b>EXAMINER</b>	<b>DATE CONSIDERED:</b>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="http://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible.</p> <p><sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 35 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p> <p><i>If you need assistance in completing the form, call 1-800-PTO-9199 (1800-786-9199) and select option 2.</i></p>	
Rev. Sept. 03 J:\Open\Djp\MaXygen ApS\USPTO\16384US04\16384US04 - PTO Form SB08A.doc	

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>ATTY. DOCKET NO.</b> 0253.410US/16384US04	<b>SERIAL NO.</b> 10/521,008
	<b>APPLICANT(s):</b> Van Den Hazel, et al.	
	<b>FILING DATE</b> 01/03/2005	<b>GROUP ART UNIT:</b> Not yet assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C46	Subramaniam, et al.,	<i>The Carboxyl Terminus of Interferon-<math>\gamma</math> Contains a Functional Polybasic Nuclear Localization Sequence</i> , Journal of Biological Chemistry, 274(1) 403-407 (1999).
C47	Tang, et al.,	Studies on the PEGylation of Protein at a Specific Site: Sulphydryl-PEGylation of 97 Cys-IFN- $\gamma$ , Acta Biochimica et Biophysica Sinica, 28(3) 1-5 (May, 1996).
C48	Taya, et al.,	<i>Cloning and structure of the human immune interferon-<math>\gamma</math> chromosomal gene</i> , The EMBO Journal, 1(8) 953-958 (1982).
C49	Trousdale, et al.,	<i>Human Alpha and Gamma Interferon Analogs in Rabbits with Herpetic Keratitis</i> , Invest. Ophth. & Vis. Sci., 26(9) 1244-1251 (1985).
C50	Waschütz, et al.,	<i>Interferon-<math>\gamma</math> variants with deletions in the AB surface loop</i> , Eur. J. Biochem., 256:303-309 (1998).
C51	Wetzel, et al.,	<i>Mutations in Human Interferon Gamma Affecting Inclusion Body Formation Identified by a General Immunochemical Screen</i> , Bio/Technology, 9:731-737 (1991).
C52	Zhang, et al.,	<i>Quantitative analysis and process monitoring of site-specific glycosylation microheterogeneity in recombinant human interferon-<math>\gamma</math> from Chinese hamster ovary cell culture by hydrophilic interaction chromatography</i> , Journal of Chromatogr. B, 712:73-82 (1998).
C53	Ziesche, et al.,	<i>A Preliminary Study of Long-Term Treatment with Interferon Gamma-1b and Low-Dose Prednisolone in Patients with Idiopathic Pulmonary Fibrosis</i> , The New England Journal of Medicine, 341(7) 1264-1269 (1999).
C54	Wetzel, et al.,	<i>Mutational Analysis of the C-terminus of Hyman Interferon-<math>\gamma</math></i> , Protein Engineering, 3:(7) pp. 611-623 (1990).
C55	Alberts, et al.,	<i>Molecular Biology of the Cell</i> , 1989.

EXAMINER	/Jegatheesan Seharaseyon/	DATE CONSIDERED:	03/30/2008
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p> <p>If you need assistance in completing the form, call 1-800-PTO-9199 (1800-786-9199) and select option 2.</p>			
Rev. Sept. 03 J:\Open\Djp\MaXygen ApS\USPTO\16384US04\16384US04 - PTO Form SB08A.doc			